Nanoparticles for efficient drug delivery and drug resistance in glioma: New perspectives

Jiyuan Liu,Fan Yang,Jinqu Hu,Xiuchun Zhang

DOI: https://doi.org/10.1111/cns.14715

2024-05-07

CNS Neuroscience & Therapeutics

Abstract:The key players in the initiation and progression of glioma. Studies have shown that angiogenesis, blood–brain barrier dysfunction, and poor lymphatic drainage are major factors in glioma development. In addition, other factors such as mutations in genes such as IDHI, TP53, and RB1, as well as PTEN and INK4 deletions, and CDK4, VEGF, and EGFR amplification also play an important role in glioma formation. Gliomas are the most common primary tumors of the central nervous system, with glioblastoma multiforme (GBM) having the highest incidence, and their therapeutic efficacy depends primarily on the extent of surgical resection and the efficacy of postoperative chemotherapy. The role of the intracranial blood–brain barrier and the occurrence of the drug‐resistant gene O6‐methylguanine‐DNA methyltransferase have greatly limited the efficacy of chemotherapeutic agents in patients with GBM and made it difficult to achieve the expected clinical response. In recent years, the rapid development of nanotechnology has brought new hope for the treatment of tumors. Nanoparticles (NPs) have shown great potential in tumor therapy due to their unique properties such as light, heat, electromagnetic effects, and passive targeting. Furthermore, NPs can effectively load chemotherapeutic drugs, significantly reduce the side effects of chemotherapeutic drugs, and improve chemotherapeutic efficacy, showing great potential in the chemotherapy of glioma. In this article, we reviewed the mechanisms of glioma drug resistance, the physicochemical properties of NPs, and recent advances in NPs in glioma chemotherapy resistance. We aimed to provide new perspectives on the clinical treatment of glioma.

pharmacology & pharmacy,neurosciences